Inverse Correspondence of AMH and FSH levels in Women Presenting
for Infertility Treatment
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Ovarian reserve refers to the finite amount of follicles, responsible for the support of the oocytes,
in the human ovary. From this pool, a dominant follicle is selected to enter into the menstrual
cycle, where the oocyte can be fertilized. This process is dependent on the interrelationship of
many hormones, such as Follicle Stimulating Hormone (FSH) and Anti-Mullerian Hormone
(AMH). FSH is a major component in a feedback loop that exists between hormones secreted from
the ovaries and pituitary gland. This inverse relationship allows the ovaries and brain to
communicate. AMH is produced by granulosa cells that surround the oocytes. Abnormal levels of
these hormones may indicate poor quality or quantity of the ovarian reserve. Preferred methods of
determining the ovarian reserve consider the patient’s chronological age, the level of Day 3 FSH,
and the follicle count through transvaginal ultrasound. The measurement of serum AMH levels is
a relatively new method that is being considered for determination of the ovarian reserve, giving a
more direct and accurate measurement. A negative association between circulating AMH and FSH
levels in reproductive aged women is examined. This study illustrates AMH levels presenting the
same
indication
of
the
FSH
levels
to
the
ovarian
reserve.

Introduction
At birth, the human ovary contains a finite amount of
primordial follicles that are responsible for the support of the
oocytes. This pool of available follicles is referred to as the
ovarian reserve. Folliculogenesis occurs when the follicles
leave the primordial pool and develop into preovulatory
follicles in the growing follicle pool. From this cohort, one
dominant follicle passes into the menstrual cycle, where the
oocyte can be fertilized. Follicle development is dependent
on the interrelationship of many hormones, such as Follicle
Stimulating Hormone (FSH) and Anti-Mullerian Hormone
(AMH), secreted from the anterior pituitary gland and the
ovaries, respectively (1). Abnormal levels of these hormones
may indicate a woman’s diminished ability or inability of
conception. Infertility refers to the inability of a woman to
become pregnant after having unprotected intercourse for a
specified amount of time, usually within a year.
Approximately 10% of the reproductive aged female
population, accounting for about 6.1 million women, in the
United States is affected by infertility. There are many
factors that contribute to infertility, including but not limited
to the quantity and quality of the ovarian reserve. Couples
struggling to become pregnant may consider fertility
treatments, including drugs and/or surgery (2).
Since
treatments can be financially and emotionaly draining, it is
important to consider the patient’s ability of becoming
pregnant based on the determination of the ovarian reserve.
The preferred methods consider the patient’s chronological
age, the level of Day 3 FSH, and the follicle count through
transvaginal ultrasound. The measurement of serum AMH
levels is a relatively new method that is being considered for

determination of the ovarian reserve, giving a more direct and
accurate measurement.
The aim of this study is to
demonstrate the association between circulating AMH and
FSH levels in women of different reproductive ages.

Methods Used to Determine Ovrian Reserve
Age
Recent trends show an increase in women who have started to
plan childbearing later in life, during their 30s and 40s.
Although studies show there is a high reduction of follicles
after the age of 35, the diminishing rate of follicles available
significantly varies among women of all ages. When the
hormones stop signaling the production of follicles and the
ovarian reserve is completely depleted, this is knows as
menopause, the final phase of a woman’s reproductive life
(3). This occurs around the average age of 51, but can occur
earlier or even later (4). Therefore, chronological age can be
a misleading factor for establishing the ovarian reserve.
FSH
FSH is needed to protect a portion of the follicles in the
growing follicle pool from atresia, stimulate the follicles to
grow, and to select the highest quality follicle from its cohort
to begin ovulation. Low levels of FSH are found during
follicle development, and high levels during ovulation. The
variation in levels of FSH is due to a feedback loop that exists
between the hormones secreted from the ovaries and pituitary
gland. As antral follicles develop in the ovaries, they excrete
Estradiol (E2) and Inhibin B. An increase in these hormones
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signal the gonatropins in the pituitary gland to discontinue the
release of FSH. Once ovulation occurs there is a diminish in
E2, which signals for an increase of FSH to be released. An
increase in FSH helps to prepare for the next cohort of
follicles in the growing pool (5). This inverse relationship is
a way for the ovaries and brain to communicate. Poor
communication can be an indicator of poor follicle quantity
(5,6). The Day 3 FSH test measures serum FSH levels on the
third day of the menstrual cycle to ensure the greatest
accuracy possible. However, this is an indirect measurement
considering FSH is dependent on other hormones of the
feedback loop.
Transvaginal Ultrasound
Ultrasonography used in conjunction with other tests, such as
Day 3 FSH, may provide a more accurate reading (4).
Transvaginal ultrasound measures the antral follicle count
(AFC), when follicles are in an advanced stage of
folliculogenesis (3). This method is a subjective evaluation,
and does not always provide an accurate follicle count (7). It
has not been proven that any method used in determining the
ovarian reserve is completely reliable. The two most widely
used methods are the ultrasonographics and FSH, both suggest
the AFC (4). A method that measures the ovarian reserve
directly would be useful.

untreated cycle for AMH and FSH so an accurate comparison
could be made regarding the hormones. Women presenting
with polycystic ovary syndrome (PCOS) were excluded from
the study.
Hormone Assay
The patients’ blood were collected in serum seperator tubes.
The samples were allowed to clot, centrifuged, decanted, and
stored at -20ºC in cryotubes. The tubes were thawed to be
analyzed. The serum levels were run in duplicate on a DSX TM
Four-Plate Automated ELISA Processing System (Dynex
Technologies; Chantilly, VA) per manufacturer’s instructions
(Beckham Coulter, Brea, CA). The limit of detection (LoD)
was 0.08 ng/mL with a 95% probability and the limit of
quantitation (LoQ) is 0.16 ng/mL at a total imprecision of
20%.
Statistical Analysis
The initial FSH tests were conducted to determine the
outcome of hormonal treatments of IVF patients. The
student’s test was performed to examine relationships between
FSH, AMH, and chronological age.
Statistical calculations were performed with SigmaPlot for
Windows, version 11.00 (Jandel Scientific Corportation, San
Rafael, CA) and MedCalc, version 11.4.20 (MedCalc
Software, Belgium). Linear regression analysis was used to
investigate the relationships between the measures of the
study. All the linear regression graphs had 95% confidence
intervals.
A receiver operator curve (ROC) used the mean levels of
FSH to consider probable ranges of AMH that can be used for
analysis.

AMH

Results

A proposed test for ovarian reserve is the circulating levels of
AMH. AMH is produced by the granulosa cells that surround
the oocytes in the primordial follicles and suppresses follicle
recruitment. As the granulosa cells enlarge, the level of AMH
is diminished, and the follicles enter the growing pool and
become regulated by FSH (8). Considering AMH is directly
involved with the primordial follicles, it is no surprise that
studies show a significant correlation with AFC (4). The
measurement of AMH serum levels may be a more direct and
accurate method of determining the ovarian reserve.
The aim of this study is to demonstrate the inverse
relationship between AMH levels and, a commonly used
method, FSH levels from a collection of blood samples in
patients undergoing treatment for infertility.

A statistical summary for each of the parameters considered in
the study are illustrated in Table 1.
In Figure 1, a relationship between FSH and chronological
age is demonstrated. There is a significant 33% increase in
FSH levels from the the <30 age group to the 31-36 age
group. Another 26% increase occurs at the age group >36.
FSH levels increased at predictable rates with the increase of
age.
A correlation is not found between AMH levels and
chronological age due to the relatively low sample size. AMH
levels decreased by 40% from the range of women classified
in the range of <30 to the range of 31-36 years. The levels
decreased only by 4% for the women >36 years. The results
are illustrated in Figure 2.
The regression analysis is used to show any linear
correlation. Figure 3 shows a correlation between serum
AMH and FSH levels.
The ROC determined 0.88 as the AMH cut off for the range
of levels. The range was rounded up to include the ranges of
above one (>1) and below one (<1), as illustrated in Table 2.

Materials and Methods
Patients
The study population consisted of 21 infertile patients ranging
in ages 26-41 with normal menstrual cycles. The blood
samples were collected on the third day of the patient’s
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Discussion
The results for the levels of FSH corresponding with age are
as expected. Age affects the quality of antral follicles, and
therefore the FSH levels show the decrease in quality (10). It
has been found that even when FSH is measured on the third
day of the cycle, the levels can vary significantly from month
to month (3). In these types of cases it would be difficult to
indicate a normal level of FSH for the patient, and the results
may be misleading. During menopause, the antral follicle
count (AFC) is not sufficient enough to produce enough
Inhibin B to reduce the level of FSH. The high level of FSH
can not be seen until the patient has reached menopause (12).
Therefore, FSH may be used as an indicator of the ovarian
reserve, but the response to the feedback loop is prolonged
and does not reveal the future ovarian reserve lifespan.
Although AMH and FSH are not directly dependent on each
other, there is an inverse correlation. When these hormones
are measured and used as indicators for fertility treatment
outcomes, AMH predicts a greater percentage of successful
pregnancies when AFC is considered (8). Considering the
faults that are found in Day 3 FSH testing, and the correlation
that is found between AMH and FSH, it only makes sense to
use the more direct and reliable measurement of the two
hormones.
Although a decrease in AMH levels are seen in older
women, it is seen in women throughout all of the age ranges.
AMH is directly related to the ovarian reserve because it is
secreted from the follicles in the primordial pool. The ovarian
reserve that a female is born with and the degree of decline of
the primordial follicle pool throughout the lifespan varies
significantly among every female. Yet, throughout the cycle,
AMH levels remain consistent (7). This makes AMH a more
reliable test that is not constrained to a time frame that it must
be measured during the menstrual cycle. AMH is a direct
measurement to the primoridal follicles that are available and
show a decrease in the available pool before any other
method, providing a huge advantage. This diagnostic test can
detect a decrease in AMH levels five years before a difference
in the levels of FSH or Inhibin B are noticed (11). There is a
correlation between AMH levels and the duration of prior
menstrual cycles. One of the first signs of approaching
menopause is the shortening of menstrual cycles. AMH
shows a correlation with the (8). Better understanding of a
patient’s ovarian reserve would allow for physicians to create
a better treatment plan for their patient. Therefore, AMH may
be used in conjunction with ultrasonography to ensure the best
possible indication of the ovarian reserve.
Compared with the indirect measurement of FSH, AMH
also has a higher positive correlation of the oocyte count

investigated in a study of IVF patients (7). Many factors, such
as age, play a role in a pregnancy’s success that can effect the
quantity and quality of the oocytes found in the follicles.
There is a correlation found between the quality of the oocytes
retrieved from an ovary after hyperstimlation (9). It is
undecided if the levels of AMH are an indicator of the
quantity of the follicles or the quality in terms of the follicle
maturity (10). In any case, the measurement is significant.
Every lab has a different scale that considers a FSH cut off
value normal for indication of a successful pregancy. It is
generally excepted that FSH under 10 mIU/mL (<10) is
normal and above 10 mIU/mL (>10) is abnormal for a female
during her reproductive years (7). It is critically important to
set a range for AMH levels as well when determining the
outcome for infertility patients. The ROC suggests 0.88
ng/ml as a cut off value for AMH levels determining
normality. Rounded >1 ng/mL in AMH levels corresponds
with the normal range for FSH levels, and <1 ng/ml in AMH
levels with the abnormal range for FSH levels. This value is
in the same range compared to other findings of the cut off
value as 0.99 ng/ml and 1.05 ng/ml (9).
The first step in AMH being accepted as the most reliable
indicator of ovarian reserve, and of infertility outcome is to
prove that AMH is at least as good of an indicator as the
commonly used tested FSH levels. This study shows the
predicted and intended correlation.
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